Trial Profile
Comparison of different QT interval correction methods for heart rate and QT beat-to-beat method in a thorough QT study of a triple monoamine reuptake inhibitor BMS-820836.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2015
Price :
$35
*
At a glance
- Drugs Liafensine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 09 Nov 2015 New trial record